Hedgehog pathway mutations and aberrant signaling in T-ALL are observed in ~20% of T-ALL cases.82 Most of the approved drugs work on the smoothened receptor, but recent studies have also identified the GLI1 TF as an important target of choice in T-ALL.82 Bongiovanni et al83 proposed targeting the crosstalk between Hedgehog signaling and the GR pathway as an effective therapeutic strategy in T-ALL. The gene discussed is NR3C1; the disease is acute lymphoblastic leukemia.